Efficiency and safety of application of combined scheme with ursodeoxycholic acid and mebeverin preparations in patients with metabolic syndrome

Efficiency and safety of application of combined scheme with ursodeoxycholic acid and mebeverin preparations in patients with metabolic syndrome

The article presents the clinical assessment data for efficiency and safety of hepatoprotector and spasmolytic administration in patients with metabolic syndrome. Application of ursodeoxycholic acid preparation in 500 mg dosage, and selective spasmolytic based on mebeverin, contribute to significant...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. P. Uspensky, N. V. Baryshnikova, Yu. A. Fominykh, R. M. Niyazov, D. V. Zakharov
Format:	Article
Language:	Russian
Published:	Open Systems Publication 2021-06-01
Series:	Лечащий Врач
Subjects:	metabolic syndrome non-alcoholic fat liver disease abdominal pain syndrome ursodeoxycholic acid mebeverin
Online Access:	https://journal.lvrach.ru/jour/article/view/561
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetic study of prolonged release capsules of mebeverine
by: A. L. Khokhlov, et al.
Published: (2017-02-01)

Non-alcoholic fatty liver disease: a heterogeneous phenotype. Pleiotropic effects of ursodeoxycholic acid
by: E. A. Ljaljukova
Published: (2023-08-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

Ursodeoxycholic acid preparations in the complex treatment of non-alcoholic fatty liver disease and diabetes mellitus
by: U. A. Khalilova, et al.
Published: (2023-06-01)

STATINS AND URSODEOXYCHOLIC ACID: COOPERATION OR NEUTRALITY?
by: I. N. Grigorieva, et al.
Published: (2016-01-01)

Flow Injection Analysis with Turbidity Detection for the Quantitative Determination of Mebeverine Hydrochloride in Pharmaceutical Formulations
by: Nagham S. Turkey, et al.
Published: (2022-02-01)

Ursodeoxycholic acid therapy in children with cholestatic liver disease
by: Gönül Dinler, et al.
Published: (1999-01-01)

Silver Nanoparticles with Mebeverine in IBS Treatment: DFT Analysis, Spasmolytic, and Anti-Inflammatory Effects
by: Mihaela Stoyanova, et al.
Published: (2025-04-01)

Effect of Ursodeoxycholic Acid Alone Verses Ursodeoxycholic Acid and Rifampicin in Obstetric Cholestasis
by: Ayesha Amjad, et al.
Published: (2025-07-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

How to avoid statin hepatotoxicity in patients with obesity and liver disease? Focus on the combination of ursodeoxycholic acid and atorvastatin
by: O. N. Korneeva, et al.
Published: (2012-12-01)

Ursodeoxycholic acid and hepatic diseases
by: G. V. Volynets, et al.
Published: (2021-06-01)

The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review)
by: I. V. Maev, et al.
Published: (2020-01-01)

SCHEME FOR COMBINED USE OF STATINS AND URSODEOXYCHOLIC ACID IN PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR EVENTS AND CONCOMITANT NON-ALCOHOLIC FATTY LIVER DISEASE: PROBLEMS OF PRACTICAL APPLICATION
by: S. N. Bel'diev
Published: (2017-03-01)

Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
by: G. Yu. Knorring, et al.
Published: (2024-08-01)

Metabolically associated fatty liver disease. What is the danger of a "safe" disease? Pathogenesis of cardiovascular complications
by: M. A. Isaikina, et al.
Published: (2025-02-01)

Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid
by: Sevim Çakar, et al.
Published: (2024-12-01)

STUDY OF URSODEOXYCHOLIC ACID INFLUENCE ON EFFICACY AND SAFETY OF STATIN THERAPY IN PATIENTS WITH DISEASES OF THE LIVER, GALL BLADDER AND/OR BILIARY TRACT (THE RAKURS STUDY)
by: S. Yu. Martsevich, et al.
Published: (2015-09-01)

Clinical experience with ursodeoxycholic acid (Urdoxa) in complex therapy of chronic viral hepatitis
by: E. V. Esaulenko, et al.
Published: (2014-09-01)

Ursodeoxycholic acid for the treatment of hepatic sarcoid: A pre-post pilot study
by: Ethan Weinberg, et al.
Published: (2024-07-01)

The use of pleiotropic effects of some gastroenterological drugs in the treatment of patients with non-alcoholic fatty liver disease and cardiovascular diseases: A review
by: Irina A. Komissarenko, et al.
Published: (2024-01-01)

The impact of the ursodeoxycholic acid as monotherapy and in the combination with the lactulose on the biochemical blood tests values of the nonalcoholic steatohepatitis patients
by: I. V. Mayev, et al.
Published: (2013-03-01)

Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases
by: Tiantian Hu, et al.
Published: (2025-02-01)

Studies on the Synthesis Process of Plant-Derived Ursodeoxycholic Acid Intermediates
by: Shaoxiong Jing, et al.
Published: (2025-03-01)

The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial
by: Yilihamu Abulitifu, et al.
Published: (2025-07-01)

The Impact of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Infants Treated with Photo-therapy: A Single-Blind Randomized Clinical Trial
by: Mohammad Sobhani Shahmirzadi, et al.
Published: (2024-10-01)

Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice
by: Manizheh Mostafa Gharehbaghi, et al.
Published: (2020-06-01)

Protective Effect of Ursodeoxycholic Acid in Experimental Endometriosis Induced Rat Model
by: Ali Seven, et al.
Published: (2023-11-01)

Host‐Microbial Cometabolite Ursodeoxycholic Acid Protects Against Poststroke Cognitive Impairment
by: Xuxuan Gao, et al.
Published: (2025-05-01)

Intestinal microbiom as a therapeutic target in treatment of chronic non-alcoholic fat liver disease
by: E. Yu. Plotnikova, et al.
Published: (2021-06-01)

Comparative chemoreactomic analysis of ornithine aspartate, S-ademethionine and ursodeoxycholic acid
by: I. Yu. Torshin, et al.
Published: (2022-01-01)

Rationale, completeness and quality of evidence for the use of ursodeoxycholic acid in neonatal hyperbilirubinemia
by: Olesya V. Zakharova
Published: (2024-05-01)

Efficiency of ursodeoxycholic acid in the frameworks of minimization of hepatotoxic potential of eradication therapy of Helicobacter pylori infection
by: D. N. Andreev, et al.
Published: (2021-06-01)

Metabolic syndrome correction in patients with non-alcoholic fatty liver disease and food behavior disorders
by: M. S. Yakovenko
Published: (2021-06-01)

Functional abdominal pain syndrome treated with Korean medication
by: Chang-Gue Son
Published: (2014-06-01)

Dynamics of changes in lipid peroxidation and antioxidant protection under the influence of complex treatment in patients with comorbid course of non-alcoholic steatohepatitis
by: O. Yu. Filippova
Published: (2019-06-01)

Combined alverine citrate and simeticonein preparation in the treatment of irritable bowel syndrome
by: Ye. A. Poluektova, et al.
Published: (2012-07-01)

Prolonged jaundice after previous SARS-CoV-2 infection: a clinical case report
by: N. G. Vacheishvili, et al.
Published: (2022-10-01)

The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials
by: Elaheh Rashidbeygi, et al.
Published: (2025-02-01)

Issues of diagnostics and treatment of abdominal pain at irritable bowel syndrome at outpatient stage of the healthcare
by: Yu. A. Kucheryavy, et al.
Published: (2015-12-01)